NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers


N/A
18 Years
N/A
Open (Enrolling)
Both
Bladder Cancer

Thank you

Trial Information

NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers


Patients who have been previously treated for bladder cancer and are at a high risk for
recurrence are being monitored for recurrence every 3 months with urine cytology and
cystoscopy as part of standard care.The NMP22 Bladder Cancer ® Test Kit has been designed to
provide an alternative to regular urine cytology. A urine sample will be provided and
divided with a portion being used to assess the NMP22 test kit and the remaining sample to
be sent to the lab for regular urine cytology. Patient charts will be reviewed by a medical
student to record age, clinical stage, pathologic stage, time to disease
progression/recurrence, site of recurrence and survival data.


Inclusion Criteria:



- · History of pTis, pT1, large (>2cm) pTa or multiple pTa bladder cancer tumours.

Written Informed Consent prior to any study-related procedures.

Exclusion Criteria:

- History of bladder cancer tumours other than those listed in inclusion

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Principal Investigator

Jonathan Izawa, MD FRCSC

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Western Ontario, Canada

Authority:

Canada: Ethics Review Committee

Study ID:

R-05-885

NCT ID:

NCT00318266

Start Date:

January 2006

Completion Date:

January 2009

Related Keywords:

  • Bladder Cancer
  • Detection of Bladder Cancer using NMP22 Urine Test Kit
  • Urinary Bladder Neoplasms

Name

Location